Desentum
  • Home
  • Technology
  • Company
  • News
  • Contact
Select Page

Desentum raised 12 million euros for advancing allergy vaccine development

by raikeeoy | Feb 8, 2024 | News

Desentum, a Finnish biopharmaceutical company with its birch pollen allergy vaccine candidate DM-101PX currently being tested in a clinical study in Canada, raised 12 M€ in a funding round arranged by an investment service company Springvest Oyj. Desentum intends to...

Viimeisimmät artikkelit

  • Desentum’s UPSIT study with birch pollen allergy treatment DM-101PX approved by Paul-Ehrlich-Institut in Germany
  • Desentum raises €28 million to develop safer, more effective allergen immunotherapy
  • New peer-reviewed publication on Desentum’s investigational birch pollen allergen immunotherapy DM-101PX
  • Desentum to present at the 2026 EAACI annual congress in Istanbul this week
  • Desentum’s 18 M€ share issue from private investors and family offices breaks a record for unlisted growth companies in Finland

Viimeisimmät kommentit

No comments to show.

DESENTUM OY

Tekniikantie 14, 02150 Espoo, Finland
info@desentum.fi

  • Follow
  • Follow

© Desentum Oy

Privacy policy
​​Cookie settings
Website: Räikee Oy

© Desentum Oy

Tietosuojaseloste
​​Evästeasetukset
Nettisivut: Räikee Oy